Aladar A. Szalay MS, PhD

Professor Aladar Szalay is internationally recognized for his transformative research and discoveries utilizing live microorganisms (such as bacteria and viruses) to locate (diagnose) and eliminate (therapy) human cancers. He founded Genelux Corporation in 2001 and served as its Chairman, President CSO & CEO from 2001 and 2014.

Under Professor Szalay’s leadership, the company raised nearly $100 million from mainly private investors for its groundbreaking research and clinical program that included four Phase 1 human trial involving the company’s lead compound, .the oncolytic vaccinia virus, GL-ONC1. More than 80 cancer patients received the experimental drug for cancer therapy and diagnosis, and, importantly, these trials also marked the first time that light emitting proteins were used in humans as diagnostic markers for cancer cells.